References
Applebaum PC: Antimicrobial resistance inStreptococcus pneumoniae: an overview. Clinical Microbiology Reviews 1992, 15: 77–83.
Johnson AR, Speller DCE, George RC, Warner M, Domingue G, Efstratiou A: Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. British Medical Journal 1996, 312: 1454–1456.
National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd Edition. Approved Standard, M7-A3. NCCLS, Villanova, PA, 1993.
Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S: In vitro and in vivo antimicrobial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 1992, 36: 573–579.
Sader HS, Erwin ME, Jones RN: In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. European Journal of Clinical Microbiology & Infectious Diseases 1992, 11: 372–381.
Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 1995, 35: 230–232.
Author information
Authors and Affiliations
Additional information
We thank Glaxo Wellcome for financial support for this work.
Rights and permissions
About this article
Cite this article
Johnson, A.P., Warner, M. & Parsons, T. Activity of grepafloxacin against respiratory isolates ofStreptococcus pneumoniae . Eur. J. Clin. Microbiol. Infect. Dis. 16, 622–623 (1997). https://doi.org/10.1007/BF02447932
Issue Date:
DOI: https://doi.org/10.1007/BF02447932